Loading…

Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide

Abstract Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally...

Full description

Saved in:
Bibliographic Details
Published in:Amyloid 2013-09, Vol.20 (3), p.179-187
Main Authors: Verwey, Nicolaas A., Hoozemans, Jeroen J.M., Korth, Carsten, van Royen, Marloes R., Prikulis, Ingrid, Wouters, Dorine, Twaalfhoven, Harry A.M., van Haastert, Elise S., Schenk, Dale, Scheltens, Philip, Rozemuller, Annemieke J.M., Blankenstein, Marinus A., Veerhuis, Robert
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483
cites cdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483
container_end_page 187
container_issue 3
container_start_page 179
container_title Amyloid
container_volume 20
creator Verwey, Nicolaas A.
Hoozemans, Jeroen J.M.
Korth, Carsten
van Royen, Marloes R.
Prikulis, Ingrid
Wouters, Dorine
Twaalfhoven, Harry A.M.
van Haastert, Elise S.
Schenk, Dale
Scheltens, Philip
Rozemuller, Annemieke J.M.
Blankenstein, Marinus A.
Veerhuis, Robert
description Abstract Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.
doi_str_mv 10.3109/13506129.2013.797389
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_23829200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427743278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</originalsourceid><addsrcrecordid>eNp9kctu1TAURS0Eog_4A4QyZJKLXzexJyBUQalUwQTG1rl-EFd-BNsBlc_iQ_gmEt0WiUlHx4O19zlaRugFwTtGsHxN2B4PhModxYTtRjkyIR-hUzJy3lNBxOP1vSL9xpygs1pvMKYMS_EUnVAmqKQYn6L5KsYl5cnXlvVko9cQOj1BAd1s8b-g-Zy67LqUf9jQxZyyDjmtEKTmD9l4Wzv4Bj7V1rXJdp_6NRd9WuqWgngbsjfdn9_9bOfmjX2GnjgI1T6_m-fo64f3Xy4-9tefL68u3l33mhPReiEGyQxx5rA_DHSvGdfYOZDWCoEZg9ENFhunQVPKiHGDEwYTpymn2Egu2Dl6deydS_6-2NpU9FXbECDZvFRFOB1Hzui4ofyI6pJrLdapufgI5VYRrDbX6t612lyro-s19vJuw3KI1vwL3ctdgbdHwCeXS4SfuQSjGqxKiiuQtK9b_YMr3vzXMFkIbdJQrLrJS1m_oT5841-PC6TE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1427743278</pqid></control><display><type>article</type><title>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Verwey, Nicolaas A. ; Hoozemans, Jeroen J.M. ; Korth, Carsten ; van Royen, Marloes R. ; Prikulis, Ingrid ; Wouters, Dorine ; Twaalfhoven, Harry A.M. ; van Haastert, Elise S. ; Schenk, Dale ; Scheltens, Philip ; Rozemuller, Annemieke J.M. ; Blankenstein, Marinus A. ; Veerhuis, Robert</creator><creatorcontrib>Verwey, Nicolaas A. ; Hoozemans, Jeroen J.M. ; Korth, Carsten ; van Royen, Marloes R. ; Prikulis, Ingrid ; Wouters, Dorine ; Twaalfhoven, Harry A.M. ; van Haastert, Elise S. ; Schenk, Dale ; Scheltens, Philip ; Rozemuller, Annemieke J.M. ; Blankenstein, Marinus A. ; Veerhuis, Robert</creatorcontrib><description>Abstract Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.</description><identifier>ISSN: 1350-6129</identifier><identifier>EISSN: 1744-2818</identifier><identifier>DOI: 10.3109/13506129.2013.797389</identifier><identifier>PMID: 23829200</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimers disease ; Amyloid beta-Peptides - analysis ; Amyloid beta-Peptides - chemistry ; Amyloid beta-Peptides - immunology ; amyloidosis ; Animals ; Antibodies, Monoclonal - biosynthesis ; brain tissue ; Capillaries - metabolism ; Capillaries - pathology ; Cerebral Amyloid Angiopathy - diagnosis ; Cerebral Amyloid Angiopathy - metabolism ; Cerebral Amyloid Angiopathy - pathology ; dementia ; Formates - chemistry ; Humans ; Hybridomas - immunology ; Immunohistochemistry ; Mice ; Plaque, Amyloid - diagnosis ; Plaque, Amyloid - metabolism ; Plaque, Amyloid - pathology ; Protein Structure, Tertiary ; Sensitivity and Specificity</subject><ispartof>Amyloid, 2013-09, Vol.20 (3), p.179-187</ispartof><rights>2013 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</citedby><cites>FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23829200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verwey, Nicolaas A.</creatorcontrib><creatorcontrib>Hoozemans, Jeroen J.M.</creatorcontrib><creatorcontrib>Korth, Carsten</creatorcontrib><creatorcontrib>van Royen, Marloes R.</creatorcontrib><creatorcontrib>Prikulis, Ingrid</creatorcontrib><creatorcontrib>Wouters, Dorine</creatorcontrib><creatorcontrib>Twaalfhoven, Harry A.M.</creatorcontrib><creatorcontrib>van Haastert, Elise S.</creatorcontrib><creatorcontrib>Schenk, Dale</creatorcontrib><creatorcontrib>Scheltens, Philip</creatorcontrib><creatorcontrib>Rozemuller, Annemieke J.M.</creatorcontrib><creatorcontrib>Blankenstein, Marinus A.</creatorcontrib><creatorcontrib>Veerhuis, Robert</creatorcontrib><title>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</title><title>Amyloid</title><addtitle>Amyloid</addtitle><description>Abstract Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimers disease</subject><subject>Amyloid beta-Peptides - analysis</subject><subject>Amyloid beta-Peptides - chemistry</subject><subject>Amyloid beta-Peptides - immunology</subject><subject>amyloidosis</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - biosynthesis</subject><subject>brain tissue</subject><subject>Capillaries - metabolism</subject><subject>Capillaries - pathology</subject><subject>Cerebral Amyloid Angiopathy - diagnosis</subject><subject>Cerebral Amyloid Angiopathy - metabolism</subject><subject>Cerebral Amyloid Angiopathy - pathology</subject><subject>dementia</subject><subject>Formates - chemistry</subject><subject>Humans</subject><subject>Hybridomas - immunology</subject><subject>Immunohistochemistry</subject><subject>Mice</subject><subject>Plaque, Amyloid - diagnosis</subject><subject>Plaque, Amyloid - metabolism</subject><subject>Plaque, Amyloid - pathology</subject><subject>Protein Structure, Tertiary</subject><subject>Sensitivity and Specificity</subject><issn>1350-6129</issn><issn>1744-2818</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1TAURS0Eog_4A4QyZJKLXzexJyBUQalUwQTG1rl-EFd-BNsBlc_iQ_gmEt0WiUlHx4O19zlaRugFwTtGsHxN2B4PhModxYTtRjkyIR-hUzJy3lNBxOP1vSL9xpygs1pvMKYMS_EUnVAmqKQYn6L5KsYl5cnXlvVko9cQOj1BAd1s8b-g-Zy67LqUf9jQxZyyDjmtEKTmD9l4Wzv4Bj7V1rXJdp_6NRd9WuqWgngbsjfdn9_9bOfmjX2GnjgI1T6_m-fo64f3Xy4-9tefL68u3l33mhPReiEGyQxx5rA_DHSvGdfYOZDWCoEZg9ENFhunQVPKiHGDEwYTpymn2Egu2Dl6deydS_6-2NpU9FXbECDZvFRFOB1Hzui4ofyI6pJrLdapufgI5VYRrDbX6t612lyro-s19vJuw3KI1vwL3ctdgbdHwCeXS4SfuQSjGqxKiiuQtK9b_YMr3vzXMFkIbdJQrLrJS1m_oT5841-PC6TE</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Verwey, Nicolaas A.</creator><creator>Hoozemans, Jeroen J.M.</creator><creator>Korth, Carsten</creator><creator>van Royen, Marloes R.</creator><creator>Prikulis, Ingrid</creator><creator>Wouters, Dorine</creator><creator>Twaalfhoven, Harry A.M.</creator><creator>van Haastert, Elise S.</creator><creator>Schenk, Dale</creator><creator>Scheltens, Philip</creator><creator>Rozemuller, Annemieke J.M.</creator><creator>Blankenstein, Marinus A.</creator><creator>Veerhuis, Robert</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201309</creationdate><title>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</title><author>Verwey, Nicolaas A. ; Hoozemans, Jeroen J.M. ; Korth, Carsten ; van Royen, Marloes R. ; Prikulis, Ingrid ; Wouters, Dorine ; Twaalfhoven, Harry A.M. ; van Haastert, Elise S. ; Schenk, Dale ; Scheltens, Philip ; Rozemuller, Annemieke J.M. ; Blankenstein, Marinus A. ; Veerhuis, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimers disease</topic><topic>Amyloid beta-Peptides - analysis</topic><topic>Amyloid beta-Peptides - chemistry</topic><topic>Amyloid beta-Peptides - immunology</topic><topic>amyloidosis</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - biosynthesis</topic><topic>brain tissue</topic><topic>Capillaries - metabolism</topic><topic>Capillaries - pathology</topic><topic>Cerebral Amyloid Angiopathy - diagnosis</topic><topic>Cerebral Amyloid Angiopathy - metabolism</topic><topic>Cerebral Amyloid Angiopathy - pathology</topic><topic>dementia</topic><topic>Formates - chemistry</topic><topic>Humans</topic><topic>Hybridomas - immunology</topic><topic>Immunohistochemistry</topic><topic>Mice</topic><topic>Plaque, Amyloid - diagnosis</topic><topic>Plaque, Amyloid - metabolism</topic><topic>Plaque, Amyloid - pathology</topic><topic>Protein Structure, Tertiary</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verwey, Nicolaas A.</creatorcontrib><creatorcontrib>Hoozemans, Jeroen J.M.</creatorcontrib><creatorcontrib>Korth, Carsten</creatorcontrib><creatorcontrib>van Royen, Marloes R.</creatorcontrib><creatorcontrib>Prikulis, Ingrid</creatorcontrib><creatorcontrib>Wouters, Dorine</creatorcontrib><creatorcontrib>Twaalfhoven, Harry A.M.</creatorcontrib><creatorcontrib>van Haastert, Elise S.</creatorcontrib><creatorcontrib>Schenk, Dale</creatorcontrib><creatorcontrib>Scheltens, Philip</creatorcontrib><creatorcontrib>Rozemuller, Annemieke J.M.</creatorcontrib><creatorcontrib>Blankenstein, Marinus A.</creatorcontrib><creatorcontrib>Veerhuis, Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Amyloid</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verwey, Nicolaas A.</au><au>Hoozemans, Jeroen J.M.</au><au>Korth, Carsten</au><au>van Royen, Marloes R.</au><au>Prikulis, Ingrid</au><au>Wouters, Dorine</au><au>Twaalfhoven, Harry A.M.</au><au>van Haastert, Elise S.</au><au>Schenk, Dale</au><au>Scheltens, Philip</au><au>Rozemuller, Annemieke J.M.</au><au>Blankenstein, Marinus A.</au><au>Veerhuis, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</atitle><jtitle>Amyloid</jtitle><addtitle>Amyloid</addtitle><date>2013-09</date><risdate>2013</risdate><volume>20</volume><issue>3</issue><spage>179</spage><epage>187</epage><pages>179-187</pages><issn>1350-6129</issn><eissn>1744-2818</eissn><abstract>Abstract Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>23829200</pmid><doi>10.3109/13506129.2013.797389</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1350-6129
ispartof Amyloid, 2013-09, Vol.20 (3), p.179-187
issn 1350-6129
1744-2818
language eng
recordid cdi_pubmed_primary_23829200
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Alzheimer Disease - diagnosis
Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Alzheimers disease
Amyloid beta-Peptides - analysis
Amyloid beta-Peptides - chemistry
Amyloid beta-Peptides - immunology
amyloidosis
Animals
Antibodies, Monoclonal - biosynthesis
brain tissue
Capillaries - metabolism
Capillaries - pathology
Cerebral Amyloid Angiopathy - diagnosis
Cerebral Amyloid Angiopathy - metabolism
Cerebral Amyloid Angiopathy - pathology
dementia
Formates - chemistry
Humans
Hybridomas - immunology
Immunohistochemistry
Mice
Plaque, Amyloid - diagnosis
Plaque, Amyloid - metabolism
Plaque, Amyloid - pathology
Protein Structure, Tertiary
Sensitivity and Specificity
title Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20characterization%20of%20novel%20monoclonal%20antibodies%20against%20the%20N-terminus%20of%20amyloid%20%CE%B2-peptide&rft.jtitle=Amyloid&rft.au=Verwey,%20Nicolaas%20A.&rft.date=2013-09&rft.volume=20&rft.issue=3&rft.spage=179&rft.epage=187&rft.pages=179-187&rft.issn=1350-6129&rft.eissn=1744-2818&rft_id=info:doi/10.3109/13506129.2013.797389&rft_dat=%3Cproquest_pubme%3E1427743278%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1427743278&rft_id=info:pmid/23829200&rfr_iscdi=true